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https://doi.org/10.1016/j.stemcr.2018.07.007SUMMARYTo facilitate understanding of human cardiomyocyte (CM) subtype specification, and the study of ventricular CM biology in particular,
we developed a broadly applicable strategy for enrichment of ventricular cardiomyocytes (VCMs) derived from human embryonic stem
cells (hESCs). A bacterial artificial chromosome transgenic H9 hESC line in which GFP expression was driven by the human ventricular-
specific myosin light chain 2 (MYL2) promoter was generated, and screened to identify cell-surface markers specific for MYL2-GFP-ex-
pressing VCMs. A CD77+/CD200 cell-surface signature facilitated isolation of >97% cardiac troponin I-positive cells from H9 hESC
differentiation cultures, with 65% expressing MYL2-GFP. This study provides a tool for VCM enrichment when using some, but not
all, human pluripotent stem cell lines. Tools generated in this study can be utilized toward understanding CM subtype specification,
and enriching for VCMs for therapeutic applications.INTRODUCTION
Human embryonic stem cell (hESC)-derived cardiomyo-
cytes (CMs) serve as an in vitro system to understand
human CM lineage development, for cardiac disease
modeling, drug discovery, toxicity, and regenerative medi-
cine (Habib et al., 2008; Braam et al., 2009; Braam et al.,
2010; Moretti et al., 2013). Existing differentiation proto-
cols generate mixed cardiovascular (CM, smooth muscle
cell, fibroblast, and endothelial cell) and CM (atrial, ven-
tricular, and nodal) populations of varying yields (He
et al., 2003; Yang et al., 2008; Kattman et al., 2011; Burridge
et al., 2014), and potentially contain contaminating and
undesired cell types that could markedly affect basic and
clinical applications of hESC-derived CMs (Habib et al.,
2008; Braam et al., 2009).
Methodologies have been developed that enrich for
CMs or different CM subtypes (Mummery et al., 2012;
Talkhabi et al., 2016). Previous studies have engineered
hESC lines to express fluorescent reporters or antibiotic
resistance elements driven by cardiac- or atrial- or ven-
tricular-specific promoters to enrich for cardiac progeni-
tors or CMs, or CM subtypes by fluorescence-activated
cell sorting (FACS) or drug selection (Bernstein and
Hyun, 2012; Den Hartogh and Passier, 2016). However,828 Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018 j ª 2018 Th
This is an open access article under the CC BY-NC-ND license (http://creativa major drawback of this approach is that genetic
manipulation of hESCs precludes use of derivatives in
downstream clinical applications. To overcome this,
some cell-surface markers for human CMs have been
identified, including SIRPA (signal-regulatory protein-a/
CD172a) (Dubois et al., 2011; Elliott et al., 2011) and
VCAM1 (vascular cell adhesion molecule 1/CD106)
(Elliott et al., 2011; Uosaki et al., 2011), which distin-
guish stem cell-derived CMs from non-CMs using flow
cytometry. These proteins, however, are not exclusively
expressed by CMs, and are only useful for identifying
CMs at certain stages of differentiation. Although prog-
ress has been made in directing CMs toward a specific
phenotype (Zhang et al., 2011; Karakikes et al., 2014),
cell-surface markers suitable for sorting subpopulations
of CMs have not yet been established.
Here, we identified a CD77+/CD200 cell-surface signa-
ture that can be utilized to enrich for hESC-derived ventric-
ular cardiomyocytes (VCMs).We generated a transgenic H9
hESC reporter line in which GFP expression was driven by
ventricular-specificmyosin light chain 2 (MYL2) (Chuva de
Sousa Lopes et al., 2006) regulatory sequences (promoter/
enhancers) derived from a MYL2 bacterial artificial chro-
mosome (BAC), and performed a flow cytometry screen.
MYL2-GFP-expressing cells (and CD77+/CD200-sortede Authors.
ecommons.org/licenses/by-nc-nd/4.0/).
populations) displayed structural, molecular, and func-
tional properties of VCMs.RESULTS
Generation of an H9 MYL2-GFP BAC Transgenic
Reporter Cell Line
AnH9 hESC BAC transgenic reporter cell line was generated
by introducing a targeting construct containing a histo-
ne2B-GFP-IRES-neomycin resistance gene cassette (H2B-
GFP-IRES-NeoR) integrated in-frame to the ATG start site
of the cardiac ventricle-specific human MYL2 gene, encod-
ing ventricular MYL2 (Figure 1A). An additional PGK-
neomycin resistance (PGK-NeoR) gene cassette enabled se-
lection of positive clones by G418 antibiotic treatment
following electroporation of the BAC targeting vector into
wild-type H9 hESCs. Based on the limited activity of a short
MYL2 promoter (Huber et al., 2007; Bizy et al., 2013), a BAC
was used so that GFP expression might more closely mimic
that of endogenousMYL2. Genomic integration of the BAC
construct in G418-resistent clones was verified by PCR
(Figure 1B). Pluripotency of each transgenic clone was
confirmed by immunofluorescence and flow cytometric
analysis of intracellular and cell-surface stem cell markers,
respectively (Figures S1A and S1B). Karyotype analyses indi-
cated normal diploid chromosomes (Figure S1C).
To monitor ventricular specification, H9 MYL2-GFP
hESCs were differentiated into CMs as embryoid bodies
(EBs) (Noseda et al., 2011) (Figure S1D). Beating EBs ap-
peared between days 7 and 10 of cardiac differentiation,
coincident with the upregulation of the cardiac-specific
genes: cardiac troponin I (TNNI3), cardiac troponin T
(TNNT2), and theMYL2 atrial isoform (MYL7) (Figure S1E).
Expression of endogenous MYL2 appeared around day 15
of differentiation (Figure S1E), which closely paralleled
MYL2-H2B-GFP-positive (MYL2(-H2B)-GFP+) detection by
flow cytometry (Figure 1C), and nuclear MYL2-H2B-GFP
epifluorescence (Figures 1D–1F; Video S1). The proportion
of the MYL2-GFP+ population increased over time, reach-
ing a variable maximum between days 20 and 25 (Figures
1C and S2A). Regardless of cardiac differentiation effi-
ciency, the proportion of CMs expressing MYL2-GFP was
similar (Figure S1F). Immunofluorescence analysis of cell
populations derived from dissociated EBs after 25 days
of cardiac differentiation demonstrated the presence of
both cardiac troponin T-positive (cTNT+)/MYL2-H2B-
GFP+ and cTNT+/MYL2-H2B-GFP-negative (MYL2-GFP)
populations (Figure 1E). Immunostaining for MYL2 re-
vealed that expression was exclusive to MYL2-H2B-GFP+/
sarcomeric a-actinin-positive CMs (Figure 1F).
To further characterize the H9 MYL2-GFP reporter cell
line, we purifiedMYL2-GFP+ cells by FACS to assess ventric-ular phenotype (Figure 2). As cardiac differentiation effi-
ciency varied between experiments, we enriched for CMs
by SIRPA-bright (SIRPA+) selection (Figure S2B) (Dubois
et al., 2011). Cell-sorting gates were conservatively chosen
based on corresponding isotype control and/or H9 parental
cells at the same stage of cardiac differentiation (Figure S2).
qRT-PCR analysis showed that day 25 MYL2-GFP+-sorted
cells were significantly enriched for both TNNT2 (cTNT)
and MYL2 compared with MYL2-GFP cells (Figure 2A).
Electrophysiological assessment revealed action potentials
from SIRPA+/MYL2-GFP+ and SIRPA+/MYL2-GFP cells to
be characteristic of ventricular and atrial CMs, respectively
(Figure 2B). Furthermore, differences in inward sodium
(Na+) and outward potassium (K+) currents in SIRPA+/
MYL2-GFP+ cells compared with SIRPA+/MYL2-GFP cells,
as measured by whole-cell voltage clamp (Figure 2C), were
consistent with previous observations in ventricular and
atrial CMs isolated from human myocardium (Varro
et al., 1993).
Taken together, these data document generation of an
H9 MYL2-GFP BAC transgenic reporter hESC line that al-
lowed for identification and purification of hESC-derived
ventricular-like CMs based on MYL2 expression.
Human ESC-Derived VCMs Express a Specific Cell-
Surface Marker Signature
To identify a cell-surfacemarker signature that could specif-
ically identify hESC-derived VCMs, we performed an unbi-
ased flow cytometry-based screen using a panel of 242
known anti-humanmonoclonal antibodies on cell popula-
tions generated from theH9MYL2-GFP reporter cell line af-
ter 25 days of cardiac differentiation in an EB culture sys-
tem. Screening allowed for simultaneous interrogation of
both MYL2-GFP+ and MYL2-GFP populations for expres-
sion of 242 surface makers (Figure 3A).
To define positive and negative hits, markers were ranked
based on expression intensity and differential frequency
within MYL2-GFP+ and MYL2-GFP populations (Figures
3B–3E). To identify markers enriching for MYL2-GFP+ cells
(positive hit) or MYL2-GFP cells (negative hit), data were
expressed as a ratio of median fluorescence intensity
(MFI), whereby the MFI value of MYL2-GFP+ cells stained
with an individual antibody, and detected with an Alexa
Fluor 647 (AF647)-conjugated second-step antibody, was
quantified in relation to the MFI value of MYL2-GFP cells
in each individual antibodywell (Figure 3D). A highMFI ra-
tio indicated a positive hit, whereas a low ratio suggested a
negative hit. The full heatmap with the MFI ratio for each
antibody tested is reported in Table S1. We furthermore
considered the differential expression of cell-surface
markers in terms of frequency within the MYL2-GFP+ and
MYL2-GFP populations (Figure 3E) to narrow down the
list of potential hits. For example, CD340 had a relativelyStem Cell Reports j Vol. 11 j 828–841 j September 11, 2018 829
AC
E F
D
B
Figure 1. Generation of an H9 MYL2-GFP BAC Transgenic Reporter Cell Line
(A) A schematic representation of the BAC targeting vector containing: a histone2B-GFP-IRES-neomycin resistance gene cassette (H2B-
GFP-IRES-NeoR) integrated in-frame to the ATG start site of the cardiac ventricle-specific human MYL2 gene, and a PGK-neomycin
resistance (PGK-NeoR) gene cassette encoding G418 resistance flanked by loxP sites (black triangles). The predicted sizes of the PCR
products using primers (P) 1–4 to detect genomic integration are indicated.
(B) RT-PCR amplification of a 1-kb band (P1 and P3) and a 0.6-kb band (P2 and P4), and long-range PCR amplification of a specific 4.1-kb
band (P1 and P2) confirmed BAC construct integration in G418-resistent clones nos 1–6. BAC DNA was used as a positive control. Genomic
DNA from non-transfected wild-type H9 hESCs was used as a negative control. M, marker. See Figure S1 for verification of H9 MYL2-GFP BAC
reporter line pluripotency and cardiac differentiation capacity.
(C) Flow cytometric quantification of MYL2-H2B-GFP expression over the time course of embryoid body cardiac differentiation (day 0–25).
Numbers indicate the percentage of GFP+ cells (see Figure S2A for cell gating strategy). Data are representative of a minimum of three
independent clones.
(D) Immunofluorescence analysis (MYL2-H2B-GFP) of a day 25 embryoid body derived from H9 MYL2-GFP hESCs. Scale bar, 100 mm. The
image is representative of a minimum of three independent clones.
(E) Immunofluorescence analysis of hESC-derived cardiomyocytes after 25 days of cardiac differentiation. MYL2-H2B-GFP-positive(+) cells
(i) were positive for cardiac troponin T (cTNT) (ii). (iii) DNA stained with DAPI. (iv) Merged image. Arrows point to MYL2-H2B-GFP+/cTNT+
cardiomyocytes. Asterisks indicate cTNT+ cardiomyocytes not expressing MYL2-H2B-GFP. Scale bar, 20 mm. Images are representative of a
minimum of three independent clones.
(F) Immunostaining for MYL2 (i) shows exclusive expression in MYL2-H2B-GFP+ hESC-derived cardiomyocytes after 25 days of cardiac
differentiation (ii and iii). MYL2-H2B-GFP+/MYL2+ cardiomyocytes were positive for a-actinin (vi), but not all a-actinin+ cells (iv) were
MYL2+ cardiomyoctes. (v) DNA stained with DAPI. Scale bar, 20 mm. Images are representative of a minimum of three independent clones.
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Figure 2. Characterization of H9 MYL2-GFP hESC-Derived Ventricular Cardiomyocytes
(A) qRT-PCR analysis of TNNT2 and MYL2 gene expression in unsorted, MYL2-GFP-negative (GFP)-, SIRPA-bright/MYL2-GFP-negative
(SIRPA+/GFP)-, and MYL2-GFP-positive (GFP+)-sorted fractions of dissociated hESC-derived embryoid bodies at day 25 of cardiac dif-
ferentiation (see Figure S2 for cell gating strategy). Data were normalized to corresponding ACTB expression, and are relative to the
unsorted hESC-derived cell population. Error bars, mean ± SD. ***p % 0.001 by Student’s t test (n = 3 technical replicates). Data are
representative of a minimum of three independent biological replicates.
(B) Electrophysiological characterization of SIRPA+/GFP+- and SIRPA+/GFP-sorted fractions of dissociated hESC-derived embryoid bodies
at days 25–40 of cardiac differentiation (see Figure S2B for cell gating strategy). (i) Representative triggered action potential (AP) traces
recorded from SIRPA+/GFP+ and SIRPA+/GFP cardiomyocytes using whole-cell current-clamp technique. (ii) Quantification of AP duration
(APD) at different times of repolarization (50% and 90%) for SIRPA+/GFP+ (n = 21) and SIRPA+/GFP (n = 18) cardiomyocytes. Error bars,
mean ± SEM. **p % 0.01 by Student’s t test. mV, millivolts; s, seconds. Data are representative of a minimum of three independent
biological replicates.
(C) Representative whole-cell currents recorded from (i) SIRPA+/GFP+ (upper panel) and (iv) SIRPA+/GFP (lower panel) cells, with an
enlarged view of the solid boxed area (ii and v), and the dashed boxed area (iii and vi) to the right of the corresponding trace. (vii)
Quantification of maximum inward Na+ currents, and maximum sustained K+ currents of SIRPA+/GFP+ (n = 21) and SIRPA+/GFP (n = 18)
cardiomyocytes. Error bars, mean ± SEM. *p % 0.05 by Student’s t test. Data are representative of a minimum of three independent
biological replicates. nA, nanoampere; s, seconds; ms, milliseconds; pA/pF, picoampere per picofarad.highMFI ratio of 2.02; however, the differential expression
was poor (Figures 3D, 3E, and S3). Although 90.6% of all
MYL2-GFP+ cells were found to express CD340, it was
also detected in 78.6% of MYL2-GFP cells.
Taking both intensity and differential expression into
consideration, we identified CD77 (also known as globo-triaosylceramide; Gb3), as a potential VCM-specific marker
(Figure 3B).With anMFI ratio of 5.08, CD77 also had a high
differential expression pattern, with 70.7% of the MYL2-
GFP+, and only 13.7% of the MYL2-GFP population
expressing the cell-surface marker. From the screen, we
also identified CD200 (also known as OX-2 membraneStem Cell Reports j Vol. 11 j 828–841 j September 11, 2018 831
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Figure 3. Identification of Positive and Negative Cell-Surface Markers Specific to hESC-Derived Ventricular Cardiomyocytes
(A) After exclusion of debris and doublets based on light scatter properties, single cells were analyzed for the expression of MYL2-GFP. The
gating strategy for the detection of MYL2-GFP+ cells was defined using parental H9 cells as a control (see Figure S2A). GFP+ and GFP
populations, represented in green and orange, respectively, were interrogated for the expression of each one of the 242 surface markers
included in the BD Lyoplate screening panel.
(B and C) Representative example of positive and negative hits, (B) CD77 and (C) CD200, identified based on median fluorescence intensity
(MFI) ratio and differential frequency (%) within GFP+ and GFP subpopulations. See Figure S3 for other potential marker candidates.
(D and E) Representative heatmaps depicting the highest-ranked positive or negative hits based on (D) MFI ratio or (E) differential
frequency (%) within GFP+ and GFP populations (see Table S1 for heatmap of complete list of 242 markers).glycoprotein) as a negative marker of hESC-derived VCMs
(Figure 3C). Less than 10% ofMYL2-GFP+ cells were shown
to express CD200, whereas over 60% of MYL2-GFP cells
stained positively for this marker, which also had the
lowest MFI ratio of 0.17 of all candidate cell-surface marker
hits. As an internal control to demonstrate the accuracy of832 Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018the screen in defining a cell-surface signature, antibodies
including anti-CD90 (THY1 [Kisselbach et al., 2009]), and
anti-CD140b (PDGFR-b [Lindahl et al., 1997]), did not
mark MYL2-GFP+ cells (Figure S3). Thus, hESC-derived
VCMs could be identified based on the positive and nega-
tive expression of select cell-surface markers.
AB
Figure 4. Validation of hESC-Derived Ventricular Cardiomyocyte Cell-Surface Marker Signature
Multi-color flow cytometry was used to simultaneously analyze the expression of surface markers CD77 and CD200, the intracellular
cardiomyocyte marker, cardiac troponin I (cTNI), and GFP at day 25 of cardiac differentiation. Data are representative of a minimum of
three independent biological replicates.
(A) MYL2-GFP-positive (green) and -negative (orange) populations were defined within single cells, after exclusion of doublets and debris
(left panel). The simultaneous expression of CD200 and CD77 was analyzed within the GFP population (middle panel, orange) and the
GFP+ population (right panel, green). See Figure S4 for co-expression of CD77 or CD200 with other marker candidates.
(B) CD77 and CD200 expression was first analyzed within the single-cell population (left panel). The expression of cTNI and MYL2-GFP was
then analyzed within the CD77/CD200+ population (middle panel, orange) and CD77+/CD200 population (right panel, green).Validation of hESC-Derived VCM Cell-Surface Marker
Signature
We postulated that the combination of CD77-positive
(CD77+) and CD200-negative (CD200) selection could
be used as a cell-surface signature for enriching a popula-
tion of hESC-derived VCMs from a heterogeneous cell pop-
ulation. Multi-color antibody panels were designed and
validated to optimize signal resolution (data not shown).
When gating on the MYL2-GFP EB-derived population
at day 25 of differentiation, the majority of cells resided
within the CD77/CD200+ subpopulation (Figure 4A). It
is unclear whether the very low numbers of CD77+ cells
present in the MYL2-GFP fraction represent true CD77+
non-VCMs, or VCMs yet to express MYL2. The majorityof the MYL2-GFP+ gated population, however, were
CD77+/CD200, with >95% of MYL2-GFP+ VCMs express-
ing CD77 (Figure 4A), thus validating the hits identified
from the screen.
When using the reverse strategy, gating on the CD77/
CD200+ population, >97%of cells were negative for cardiac
troponin I (cTNI), and virtually no CD77/CD200+ cells
were MYL2-GFP+ (Figure 4B). Conversely, when gating for
CD77+/CD200, 95% ± 2.7% of cells were cTNI+, and
63.8% ± 1.3% were cTNI+/MYL2-GFP+ VCMs (Figures 4B
and 5E), providing further validation for CD77+/CD200
as a cell-surface marker signature of hESC-derived CMs.
The minor proportion of CD77+/CD200 cells that were
not MYL2-GFP+, might be more immature VCMs not yetStem Cell Reports j Vol. 11 j 828–841 j September 11, 2018 833
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Figure 5. CD77 Expression Highly Correlates with hESC-Derived Ventricular Cardiomyocyte Phenotype
All analysis is of the same population. Data are representative of a minimum of three independent biological replicates.
(A) Correlation of cTNI and (i) CD77, (ii) SIRPA, or (iii) MYL2-GFP in hESC-derived populations at day 25 of cardiac differentiation by flow
cytometry.
(B–E) Representative plots depicting cTNI/MYL2-GFP cell populations (right panel, green plots) at day 25 of cardiac differentiation, after
gating on different cell populations defined by distinct surface marker signatures: (B) SIRPA+/CD90; (C) SIRPA+/CD140b; (D) SIRPA+/
CD200; and (E) CD77+/CD200 (left panel, boxed area).
(F) Left panel: SIRPA+/CD77 (yellow) and SIRPA+/CD77+ (green) cell populations were defined within single cells. Right panel: histograms
depicting MYL2-GFP expression within SIRPA+/CD77 and SIRPA+/CD77+ cell populations.expressing MYL2, or represent other CM lineages. Co-
expression of other positive hits from the cell-surface
marker screen was also evaluated (Figure S4A); however, us-
ing additional positive markers for the cell-surface signa-
ture did not improve enrichment of the MYL2-GFP+ VCM
population (data not shown).834 Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018Expression of CD77 was mutually exclusive of cell-sur-
face markers negatively expressed byMYL2-GFP+ cells (Fig-
ure S4B). These markers, which include CD31, CD49a,
CD49b, CD90, CD140b, CD141, and epidermal growth fac-
tor receptor, are expressed by endothelial cells, fibroblast
cells, smooth muscle cells, and other non-CMs that
(legend on next page)
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correlated with CD200 expression (Figure S4B). These data
demonstrated that CD77+/CD200 could be used to isolate
a nearly pure CM population enriched for VCMs.
Enrichment of VCMs from hESC-Derived Populations
with a Cell-Surface Signature
Co-staining of CD77 and cTNI by flow cytometry estab-
lished a strong correlation of the two markers (Figure 5Ai),
confirming that CD77 was specifically expressed within
the CM lineage in differentiated populations generated
from hESCs. SIRPA also displayed clear co-expression
with cTNI in our cultures at day 25 of cardiac differentia-
tion (Figure 5Aii). To determine whether the expression
of CD77 on the cell surface of hESC-derived CMs can be
used to enrich for VCMs, combinations of known CM
marker signatures were compared together with cell-sur-
face markers identified in this study (Figures 5B–5F). Use
of the H9MYL2-GFP reporter cell line allowed for the inter-
rogation of VCM enrichment in populations gated blindly
based upon the expression of positive and negative cell-sur-
face markers. Importantly, virtually all MYL2-GFP+ cells
(4.3% of the total starting cell population) co-expressed
cTNI, and made up 30% of the cTNI+-CM population in
the differentiation culture (Figure 5Aiii). Cells expressing
the previously identified stem cell-derived CM marker,
SIRPA (Dubois et al., 2011), not included in the Lyoplate
Human Cell Surface Marker Screening Panel, were posi-
tively selected for while excluding cell types expressing
CD90 (Figure 5B) or CD140b (Figure 5C), surface markers
specific for non-CMs (Lindahl et al., 1997; Kisselbach
et al., 2009; Dubois et al., 2011). Gating for SIRPA+/
CD90 and SIRPA+/CD140b subpopulations resulted in
90% and 86.6% of cells staining positive for cTNI by intra-
cellular flow cytometry, respectively, with up to 40% of
cells expressing MYL2-GFP (Figures 5B and 5C). Enrich-
ment of MYL2-GFP+ cells was improved using CD200 as a
negative selection marker, with 50% of the 96.8%
cTNI+-CM-enriched SIRPA+/CD200 population express-
ing MYL2-GFP (Figure 5D).
However, when selecting for CD77+ cells together with
CD200 cells, MYL2-GFP+ VCMs were enriched from 4.3%
in the starting total cell population to 64.7% in theFigure 6. Validation of Ventricular Cardiomyocyte Enrichment fro
(A) qRT-PCR analysis of TNNT2, MYL2, MYH6, MYH7, GJA5, and NPPA
CD200-sorted fractions of dissociated hESC-derived embryoid bodi
corresponding ACTB expression, and are relative to H9 hESC-derived e
three independent biological replicates.
(B) Immunofluorescence analysis of H9 hESC-derived CD77+/CD200-s
were stained with cTNT. DNA was stained with DAPI. Scale bar, 50 m
biological replicates.
(C) qRT-PCR analysis of CD77, CD200, and SIRPA gene expression in hum
to corresponding GAPDH expression.
836 Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018CD77+/CD200 gated population (Figures 5Aiii and 5E).
The CD77+/CD200 cell-surface marker signature enriched
for a nearly pure cTNI+ CM population (Figure 5E). Further-
more, the CD77+ population was a subset of SIRPA+ cells
selectively enriched forMYL2-GFP+VCMs (Figure 5F). These
data demonstrated that, although SIRPA allows for the isola-
tion of populations highly enriched for CMs, CD77 further
enriched for VCMs. For confirmation, molecular analyses
revealed that CD77+/CD200 cells sorted following
25 days of cardiac differentiation expressed an extensive
panel of cardiac markers, including TNNT2, MYL2, MYH6,
MYH7, GJA5, and NPPA (Figure 6A). To ensure that the
cell-surface signature was effective not only in our MYL2-
H2B-GFP transgenic H9 cell line, but also for parental H9
cells, we performed immunocytochemical analysis of
parental H9 hESC-derived CD77+/CD200-sorted cells
with an anti-MYL2 antibody after 25 days of EB cardiac dif-
ferentiation, and further verified the high proportion of
VCMs in these cultures (Figure 6B). CD77 also discriminated
between atrial and ventricular cells in human hearts, as
CD77 expression was significantly higher in human fetal
ventricular tissue than atrial (Figure 6C).
To determine whether the cell-surface marker signature
identified in this study could be accurately used to define
a stage of cardiac differentiation, we monitored expression
of CD77, CD200, SIRPA, and CD90 over the time course of
differentiation (Figure S5). The expression pattern of the
cell-surface signature (CD77+/CD200/SIRPA+/CD90)
showed a strong correlation with the emergence of
MYL2-GFP+ VCMs (Figure S5A). We also compared the
use of the cell-surface protein VCAM1 with our CD77+/
CD200 cell-surface signature in the identification of
CMs. Antibodies to VCAM1 are effective at identifying
CMs from cardiac differentiation cultures from days 9 to
14 (Elliott et al., 2011; Uosaki et al., 2011). We performed
EB cardiac differentiation of the parental H9 cell line and
harvested cells for FACS at day 12 of differentiation. Subse-
quent immunocytochemical analysis of VCAM1-sorted
cells demonstrated that antibodies to VCAM1 were able
to yield populations of 92.4% ± 11.9% (n = 5 fields of
view/n = 4 biological replicates) cTNT+ cells (Figure S5E).
At day 12 of differentiation,MYL2+ cells were not observed,m hESC-Derived Populations with a Cell-Surface Signature
gene expression in SIRPA+/CD77-, CD77/CD200+-, and CD77+/
es at day 25 of cardiac differentiation. Data were normalized to
mbryoid bodies at day 0. Data are representative of a minimum of
orted cells after 25 days of cardiac differentiation. Cardiomyocytes
m. Images are representative of a minimum of three independent
an 15-week fetal atrial and ventricular tissue. Data were normalized
consistent with above studies showing thatMYL2 gene and
protein expressionwas first evident around day 15 of differ-
entiation (Figures S1 and 1C). These results were in contrast
to day 25 of differentiation, when no VCAM1 expression
was detectable on cell populations generated from the H9
MYL2-GFP reporter cell line (Table S1). These results
confirmed previous findings that VCAM1 is effective for
identifying CMs at relatively early stages of cardiac differ-
entiation (Elliott et al., 2011; Uosaki et al., 2011), empha-
sizing the use of the CD77+/CD200 cell-surface signature
for enrichment of differentiated VCMs.
To evaluate the robustness of CD77 as a cell-surface
marker to enrich for VCMs in other hESC lines, we analyzed
bothRUES2- andH1ESC-derivedCMs forMYL2 expression,
both before and after sorting for CD77+/CD200. Following
25 days of EB cardiac differentiation, selecting for CD77+/
CD200 cells resulted in a significant fold enrichment of
ventricular (MYL2-expressing) CMs in both RUES2 and H1
hESC lines (Figure S6A). We further analyzed expression of
CD77 in CMs derived from two independent human wild-
type induced pluripotent stem cell (iPSC) lines by flow
cytometric analysis (Figure S6B). However, putative CM
populations in both iPSC lines exhibited little to no CD77
expression, for reasons that are not clear, but may reflect
negligible presence of VCMs in the tested cultures.
We also investigated whether the CD77+/CD200 cell-
surface signature would be effective for enrichment of
VCMs derived from monolayer cultures differentiated ac-
cording to a two-dimensional monolayer protocol (Bur-
ridge et al., 2014). Using this protocol, expression of the
MYL2-H2B-GFP transgene occurred at approximately day
40 of differentiation (data not shown), much later than
observed with the EB protocol (Figure 1C). Accordingly,
cells were cultured until day 60 (when MYL2-H2B-GFP+
cells were widely evident). Sorting for CD77+/CD200
resulted in a 2- to 5-fold enrichment of VCMs from
monolayer cultures (Figure S6C), somewhat less than that
obtained from EB cultures.
Together, the findings from these studies demonstrated
the use of cell sorting with the cell-surfacemarker signature
CD77+/CD200 for enrichment of VCMs when using
some, but not all, PSC lines.DISCUSSION
Despite continuous improvements in efficiency and repro-
ducibility, current differentiation methodologies generate
heterogeneous populations of cardiovascular cells and/or
CMswith varying degrees ofmaturity, necessitating further
refinements to maximize use of hESC-derived CMs in
certain basic and clinical applications (Habib et al., 2008;
Braam et al., 2009).FACS is the method of choice when very high purity of a
desired cell population is required, when the target cell
population expresses a very low level of the identifying sur-
face marker, or when cell populations require separation
based on differential marker frequency (Basu et al., 2010).
Using an H9 MYL2-GFP BAC transgenic reporter cell line,
we screened a panel of >240 known commercially available
antibodies and identified CD77 as a surface protein ex-
pressed on hESC-derived VCMs. CD77, also known as
Gb3, is a glycolipid characteristically expressed on Burkitt
lymphoma cells and a subset of B lymphocytes (Nudelman
et al., 1983; Mangeney et al., 1991). Interestingly, the gene
encoding the enzyme responsible for the synthesis of
CD77/Gb3, CD77/Gb3 synthase (Gb3S or a1,4-galactosyl-
transferase), is strongly expressed in normal human heart
tissue (Kojima et al., 2000).
Using the cell-surface marker signature, CD77+/CD200,
we isolated populations consisting of >97% CMs from
differentiating hESCs, with 65% being VCMs. CM identity
was verified by flow cytometry, immunocytochemistry,
and qRT-PCR. Furthermore, CD77+/CD200 selection
enabled CM enrichment of >97% (65% MYL2-GFP+) from
a cell source comprising only 15% cTNI+ CMs (4%
MYL2-GFP+). Regardless of differentiation efficiency, the
CD77+/CD200 population always strongly correlated
with the MYL2-GFP+ population, highlighting the use of
CD77+/CD200 selection in enriching for VCMs, even in
the setting of low differentiation efficiencies. Enrichment
was effective using both EB and monolayer cardiac differ-
entiation protocols.
Another advantage to using the cell-surfacemarker signa-
tureCD77+/CD200 to isolate a nearly pureCMpopulation
enriched for ventricular cells is the ease of gating the popu-
lation for cell-sorting applications.We found SIRPA expres-
sion to be a continuum, which made accurate gating of a
true CM population a challenge without the use of addi-
tional negative markers or by fixing and performing intra-
cellular cTNI staining. Even so, gating for SIRPA+/CD90
or SIRPA+/CD140b populations led to the collection of
some (10%–13%) non-CM contaminants, and the overall
population of cTNI+ cells contained more MYL2-GFP
thanMYL2-GFP+ cells. Using CD200 as a negative selection
marker together with SIRPA allowed for easy gating of a
more highly enriched pan-CMpopulation. However, stain-
ing for CD77 and CD200 expression allowed for robust
gating of a clearly separated CD77+/CD200 population
rich in CMs of ventricular phenotype, when compared
with other known cell-surface marker combinations.
Enrichment for VCMs using CD77+/CD200 selection
was effective not only in our MYL2-H2B-GFP transgenic
H9 cell line, but also for parental H9 cells, and RUES2 and
H1 hESC lines. One important caveat is that in contrast to
our results using the hESC lines (RUES2, H1, and H9),Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018 837
flowcytometric analysis ofCD77expression inputativeCM
(SIRPA+/CD200) populations derived from two human
wild-type iPSC lines exhibited little to noCD77 expression,
although CD77 was expressed in human fetal ventricular
tissue. Future analysis of other hESC and iPSC lines and/or
use of RNA probes to test CD77 expression in these lines
will further address the use of CD77 as a marker.
In summary, identification of CD77 as a CM marker will
facilitate access to highly enriched populations of VCMs
derived from hESCs to enable development of high-
throughput pharmacological assays, and generation of
defined populations for regenerative therapies. Moreover,
tools generated in this study could serve to improve and
standardize cardiac differentiation methodologies that spe-
cifically enrich for VCMs, and advance our understanding
of CM subtype specification, commitment, andmaturation.EXPERIMENTAL PROCEDURES
Generation of the H9 MYL2-GFP BAC Transgenic
Reporter Cell Line
The reporter construct, encoding two transcriptional units, a
1.12-kb GFP cDNA, 570-bp IRES promoter, and a 1.12-kb NeoR
gene cassette, and a 1.38-kb PGK promoter and a NeoR gene
cassette, were generated using standard cloning techniques, and
was recombineered into a human BAC vector. The GFP cDNA
was integrated in-frame to the ATG state site of the endogenous
MYL2 locus. BAC DNA was purified using a NucleoBond Xtra
Maxi endotoxin-free kit (Macherey-Nagel) according to the manu-
facturer’s instructions. Electroporation was performed as described
previously (Costa et al., 2007), with modifications as detailed. In
brief, H9 (WA09) hESCs (WiCell Research Institute) were cultured
on BDMatrigel (BDBiosciences)matrix-coated tissue culture plates
to 70% confluence. Cells were harvested using 0.05% trypsin-
EDTA (Thermo Fisher Scientific) and resuspended in hESCmainte-
nance medium supplemented with 10 mM Y-27632 (Sigma-Al-
drich). Purified BAC DNA (50 mg) was added to 1 3 107 hESCs in
a 4-mm cuvette, cells were electroporated using the parameters
320 V and 200 mF (Gene Pulser Xcell, Bio-Rad), and immediately
transferred to Matrigel-coated plates in hESC maintenance me-
dium with 10 mM Y-27632. Medium was replaced daily and
G418 (Corning) selection was applied 3 days after electroporation
(2 days at 50 mg/mL, 2 days at 100 mg/mL, and 150 mg/mL there-
after). Surviving clones were picked, expanded, and verified by
RT-PCR (Figure 1B). Of the six clones shown, nos 1–3 were used
predominantly throughout the study. The data presented
throughout the manuscript is representative of a minimum of
three independent H9 MYL2 clones. Further, upon excision of
the PGK-NeoR gene cassette, no difference in MYL2-GFP expres-
sion was observed (data not shown).Maintenance and Cardiac Differentiation of hESCs
All procedures and use of human-derived stem cell lines were
approved by the Institutional Review Board at the University of
California, San Diego.838 Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018H9MYL2-GFP hESCs and H9 control hESCs were maintained on
Matrigel-coated plates in irradiated mouse embryonic fibroblast
(MEF) (GlobalStem)-conditioned hESC medium consisting of
DMEM/F-12 supplemented with 20% (v/v) KnockOut Serum
Replacement, 100 mM non-essential amino acids, 2 mM L-gluta-
mine, 55 mM b-mercaptoethanol (all from Thermo Fisher
Scientific), and 20 ng/mL human basic fibroblast growth factor
(PeproTech). Cellswere passaged as small colonies, following disso-
ciation with 1 mg/mL dispase (Thermo Fisher Scientific).
Prior to differentiation, hESCs were cultured on MEFs in hESC
medium for 2–3 days to 90% confluence. EBs were differentiated
to the cardiovascular lineage as described previously (Yang et al.,
2008; Dubois et al., 2011; Kattman et al., 2011), withmodifications
as detailed and as shown in Figure S1D. At the indicated time
points, EBs were harvested and dissociated to single cells using pre-
viously described methods (Dubois et al., 2011). In brief, EBs
were washed and incubated in dissociation solution consisting of
1 mg/mL collagenase type II (Worthington) in Hank’s balanced
salt solution (Corning) with 5 mM HEPES (Corning), overnight
at room temperature (RT) with gentle shaking. On the following
day, an equal amount of dissociation solution supplemented
with 1 mg/mL BSA (Thermo Fisher Scientific), 0.1 mM EGTA
(Sigma-Aldrich), and 10 mM taurine (Sigma-Aldrich) was added
to the cell suspension, and EBs were pipetted gently to dissociate
the cells. After dissociation, cells were centrifuged (200 3 g for
5 min), filtered (100 mm cell strainer), and used for analysis.RT-PCR, Long-Range PCR, and Real-Time qPCR
Total RNA was isolated using an RNeasy Micro or Mini Kit
(QIAGEN) according to the manufacturer’s instructions. RNA
(100 ng to 1 mg) was reverse transcribed into cDNA using random
hexamers or oligo(dT) with Superscript III First-Strand Synthesis
System (Thermo Fisher Scientific). RT-PCR, and long-range PCR,
to confirmBACDNA integration (Figure 1B), were performed using
MyTaq Red Mix (Bioline) and a MasterAmp Extra-Long PCR Kit
(Epicentre) used as described previously (Frazer et al., 2007),
respectively. Bands were analyzed by agarose gel electrophoresis.
qRT-PCRwas performed on a CFX96 Real-Time PCRDetection Sys-
tem (Bio-Rad) using IQ SYBR green supermix (Bio-Rad). All qRT-
PCR reactions were performed in triplicate. Expression levels
were normalized to b-actin (ACTB) or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), and assessed using the comparative
change in threshold cycle (Ct) method. After normalization, sam-
ples were plotted relative to hESC-derived EBs at day 0 or unsorted
hESC-derived cell populations at day 25 of cardiac differentiation.
Primers were designed using the NCBI Primer-BLAST software tool
and are listed in Table S2. Human 15-week fetal atrial and ventric-
ular tissue was purchased from Novogenix Laboratories, and hu-
man atrial and ventricular tissue was acquired from the University
of California SanDiego. RNA fromhuman tissuewas isolated using
an RNeasy Fibrous Tissue Mini Kit (QIAGEN).Immunocytochemistry
H9 MYL2-GFP BAC transgenic clones or single hESC-derived CMs
after 25 days of cardiac differentiation were plated on 35-mmMa-
trigel-coated plates in MEF-conditioned hESC or differentiation
media, respectively, and cultured for 3 days. Cells were washed
with PBS (Corning), fixedwith 4%paraformaldehyde (ElectronMi-
croscopy Services) for 15 min at RT, and permeabilized with 0.2%
Triton X (Sigma-Aldrich) for 10 min at RT. After three washes with
PBS, cells were blocked in 2% fish skin gelatin (Sigma-Aldrich) for
1 hr at RT, then incubated with 1:100 mouse anti-cTNT (Abcam,
ab8295), 1:200 rabbit anti-MYL2 (Proteintech, 10906-1-AP),
and/or 1:100 mouse anti-sarcomeric a-actinin (Sigma-Aldrich,
A7811), in blocking solution overnight at 4C. After staining, cells
werewashed three timeswith PBS, and,whennecessary, were incu-
bated with fluorescently conjugated secondary antibodies: 1:400
donkey anti-mouse Alexa Fluor 555, 1:400 donkey anti-rabbit
Alexa Fluor 488, or 1:400 donkey anti-rabbit Alexa Fluor 647 (all
Thermo Fisher Scientific) in blocking solution for 1–2 hr at RT in
the dark. Cells werewashed again as above, andnuclei were stained
with DAPI (Sigma-Aldrich) diluted in PBS for 5 min at RT. Cover-
slips were attached using mounting medium (Dako), and the
standing edge of each plate was removed using a scalpel that had
been passed through a flame. The plate base was then glued to a
glass slide, and imaged with an Olympus FluoView FV1000
Confocal Microscope.Cell-Surface Antibody Screening
After 25 days of differentiation, a single-cell suspension of H9
MYL2-GFP hESC-derived cells was obtained by overnight collage-
nase II digestion, as described, and resuspended in BD FACS Pre-
Sort Buffer (BD Biosciences) with the addition of 10 kU/mL DNase
II, penicillin, and streptomycin. Cells were then stained using the
BD Biosciences BD Lyoplate Human Cell Surface Marker Screening
Panel following the included product protocol, and as described
previously (Yuan et al., 2011). In brief, cells were dispensed into
96-well round-bottom plates (BD Biosciences) at 1 3 106 cells per
well. Antibodies in the BD Lyoplate Screening Panel Plates were re-
constituted with 13 PBS and added to the corresponding wells of
the plates containing the single-cell suspension. Cells were stained
live on ice for 20 min, washed with Pre-Sort Buffer containing
DNase II, penicillin, and streptomycin, and stainedwith the appro-
priate AlexaFluor 647-conjugated IgG secondary antibody for
20 min in the dark. Cells were washed again and resuspended in
Pre-Sort Buffer containing DNase II, penicillin, and streptomycin.
Cells were then analyzed on a BD FACSCanto II systemwith aHigh
Throughput Sampler reader (BD Biosciences). Data were analyzed
with BD FACSDiva software (BD Biosciences) to determine the
expression of each of the antibodies screened within the MYL2-
GFP+ and MYL2-GFP subpopulations. The median values of the
antigen screened were first normalized to their appropriate isotype
control. A ratio was then generated between MYL2-GFP+ and
MYL2-GFP cells using the normalized median values. Any anti-
gen that showed a ratio of greater than 1.5, or less than 0.5, was
then further analyzed. Microsoft Excel 2007 was used for the gen-
eration of heatmaps. The full heatmap with the MFI ratio for each
antibody tested is reported in Table S1.Multi-Color Flow Cytometry
Single-cell suspensions obtained at the indicated times of cardiac
differentiation were resuspended in BD Stain Buffer (BD Biosci-
ences) and stained with different combinations of antibodies
against cell-surface markers (antibodies are detailed in Table S3).Cells were stained for 20 min at RT in the dark. For the detection
of intracellular cTNI, cells were fixed and permeabilized after the
surface marker stain using a BD Cytofix/Cytoperm Solution Kit
(BD Biosciences). In brief, cells were incubated with fixation/per-
meabilization solution for 20 min at RT, then washed twice with
BD Perm/Wash Buffer and incubated with AlexaFluor anti-cTNI
antibody for 20 min at RT in the dark. Following antibody stain-
ing, cells were washed with, and resuspended in, BD Stain Buffer
and analyzed on a BD LSRFortessa (BD Biosciences). Parental H9
cells and isotype controls were used to define the cytometric
gates.
Cell Sorting
A single-cell suspension was obtained by overnight collagenase II
digestion, as described, washed once in PBS, and then resuspended
in Pre-Sort Buffer containing DNase II, penicillin, and strepto-
mycin. Cells were stained on ice with fluorochrome-conjugated
antibodies against CD77, CD200, and/or CD172a (SIRPA) (anti-
bodies are detailed in Table S3) in the necessary combinations for
sorting the various immunophenotypes as detailed. Cells were
washed again and resuspended in Pre-Sort Buffer containing
DNase II, penicillin, and streptomycin. Cells were then sorted
using a BD FACSAria III Cell Sorter (BD Biosciences) using a
100-mm nozzle at an approximate pressure of 20 psi. Cells were
collected in differentiation medium before preparation for qRT-
PCR, immunocytochemistry, and electrophysiology analysis, as
described.
Electrophysiology
Sorted SIRPA+/GFP+ and SIRPA+/GFP hESC-derived CM popula-
tions (Figure S2B) were plated on 35-mm Matrigel-coated plates
in differentiation media and cultured for 3 days. Only spontane-
ously beating cells were used for data collection. The presence/
absence of GFP was confirmed by microscopic observation. Sin-
gle-cell patch-clamp recordingswere performedusing anAxopatch
200B Amplifier (Axon Instruments) and digitized using a Digidata
1440A Digitizer (Axon Instruments), as described previously
(Ouyang et al., 2005). Data acquisition and analysis were per-
formed using Clampex 10.2 and Clampfit 10.2 software (Axon In-
struments), respectively. Action potentials were recorded under
whole-cell current-clamp conditions, and whole-cell Na+ and K+
currents were recorded under voltage-clamp conditions. The resis-
tance of the patch electrodes ranged from 4 to 6 MU. The standard
external solution contained: 150 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose (pH 7.4
adjustedwithNaOH). The intracellular pipette solution contained:
5 mM NaCl, 150 mM KCl, 1 mM MgCl2, 2 mM EGTA, 1 mM
MgATP, and 10 mMHEPES (pH 7.2 adjusted with KOH). All exper-
iments were performed at RT (20C–22C).
Statistical Analysis
In all quantitation experiments, results are expressed asmean ± SD
or SEM. Statistical differences between two or more sets of data
were determined using an unpaired Student’s t test or one-way
ANOVA, respectively. A value of p% 0.05 was considered statisti-
cally significant. All statistical calculations were performed using
GraphPad Prism 6 software.Stem Cell Reports j Vol. 11 j 828–841 j September 11, 2018 839
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